Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice

被引：0

作者：

Krekeler, G. ^{[1
]}

Neuhof, A. ^{[1
]}

Dreyling, M. ^{[2
]}

Hess, G. ^{[3
]}

Kalanovic, D. ^{[1
]}

机构：

[1] Pfizer Pharma GmbH, Berlin, Germany

[2] Univ Munich, Munich, Germany

[3] Johannes Gutenberg Univ Mainz, D-55122 Mainz, Germany

来源：

Oncology Research and Treatment | 2015年 / 38卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P226

引用

页码：66 / 67

页数：2

共 50 条

[1] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
Krekeler, G.
Herzberg, C.
Dreyling, M.
Hess, G.
Kalanovic, D.
ONKOLOGIE, 2013, 36 : 139 - 140
[2] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
Krekeler, G.
Neuhof, A.
Dreyling, M.
Hess, G.
Kalanovic, D.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S656 - S656
[3] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
Krekeler, G.
Dreyling, M.
Hess, G.
Kalanovic, D.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 144 - 145
[4] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
Krekeler, G.
Herzberg, C.
Dreyling, M.
Hess, G.
Kalanovic, D.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S850 - S851
[5] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
Dreyling, M.
Krekeler, G.
Neuhof, A.
Woike, M.
Hess, G.
Kalanovic, D.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 156 - 156
[6] Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
Dreyling, M. H.
Hess, G.
Woike, M.
Krekeler, G.
ANNALS OF ONCOLOGY, 2018, 29 : 362 - 362
[7] Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
Dreyling, M.
Hess, G.
Krekeler, G.
ANNALS OF ONCOLOGY, 2017, 28
[8] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
Dreyling, M.
Hess, G.
Woike, M.
Krekeler, G.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 48 - 48
[9] Evaluation of safety, tolerability and efficacy of Temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
Dreyling, M.
Hess, G.
Krekeler, G.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 72 - 72
[10] Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
Dreyling, M.
Krekeler, G.
Neuhof, A.
Woike, M.
Hess, G.
Kalanovic, D.
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →